Zevtera (ceftobiprole medocaril sodium)
Research Synopsis
- Ceftobiprole medocaril (Zevtera) is a new cephalosporin antibiotic effective against methicillin-resistant Staphylococcus aureus (MRSA) and several other resistant bacteria.
- Research indicates that ceftobiprole exhibits comparable efficacy to vancomycin in treating serious bacterial infections, including complicated skin infections.
- In multiple studies, ceftobiprole demonstrated low minimum inhibitory concentration (MIC) values against both methicillin-susceptible and resistant strains, with minimal development of resistance observed over time.
- Ceftobiprole's effectiveness extends beyond MRSA, showing action against other pathogens like Enterococcus faecalis and strains of pneumonia, although it is less effective against ESBL-producing Enterobacteriaceae.
- Pharmacokinetic studies reveal that ceftobiprole is rapidly converted to its active form upon administration and shows effective distribution in body tissues, including bones.
- Clinical trials indicate a high cure rate and good tolerance among patients with complicated skin infections treated with ceftobiprole, revealing a similar rate of adverse events compared to traditional therapies.
- The prodrug formulation (ceftobiprole medocaril) allows enhanced solubility and subsequent dosing flexibility, making it suitable for intravenous use.
- Compatibility studies show that ceftobiprole can be combined with certain other medications but can also exhibit incompatibility with a significant number of drugs, indicating the importance of careful administration.
- Ceftobiprole's low binding to plasma proteins and mild renal elimination profile mean that it may require dosing adjustments for patients with kidney dysfunction.
- Overall, ceftobiprole represents a promising new treatment option in the face of rising antibiotic resistance, with sound efficacy and safety profiles in clinical settings.
Zevtera (ceftobiprole medocaril sodium)
Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
London, UK
2 hours ago
1 Received
- * Both antibiotics showed similar minimum inhibitory concentrations (MICs) and were effective in reducing MRSA counts in the infected tissue.
- * The results indicate that ceftobiprole medocaril is as effective as vancomycin for treating MRSA infections and does not promote the development of antibiotic-resistant bacteria.
$100 - $150
Hourly Rate
Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.
London, UK
2 hours ago
1 Received
- Ceftobiprole is a new cephalosporin antibiotic that shows strong effectiveness against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
- The drug demonstrated low minimum inhibitory concentration (MIC) values for both methicillin-susceptible and methicillin-resistant strains, with only a slight increase in resistance observed after extensive exposure.
- In further tests, ceftobiprole was found to be bactericidal against a majority of tested strains, and the likelihood of developing resistance to it was very low even after multiple passages in subinhibitory conditions.
$100 - $150
Hourly Rate
Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia.
London, UK
2 hours ago
1 Received
- * In a study using mice, treatments with ceftobiprole, ceftriaxone, and cefepime showed similar effectiveness against infections from certain bacteria like Haemophilus influenzae and Enterobacter cloacae.
- * However, for infections caused by ESBL-producing Klebsiella pneumoniae, none of the treatments showed significant benefits compared to no treatment at all.
$100 - $150
Hourly Rate
Anti-MRSA beta-lactams in development.
London, UK
2 hours ago
1 Received
- - Ceftobiprole medocaril is the leading anti-MRSA beta-lactam currently in clinical trials and has shown it works as well as vancomycin in its first Phase III trial.
- - Phase II trials have begun for PPI0903, another injectable drug similar to ceftobiprole, which targets a broad range of bacteria, including MRSA.
- - RO4908643, a carbapenem antibiotic, is also undergoing Phase II trials but has a weaker effect against MRSA compared to the others.
$100 - $150
Hourly Rate
Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788.
London, UK
2 hours ago
1 Received
- Ceftobiprole medocaril is a prodrug currently in phase III clinical trials aimed at treating serious bacterial infections, including MRSA, and is developed by Basilea Pharmaceutica in collaboration with Johnson & Johnson.* -
- It is designed to be administered intravenously and demonstrates a broad spectrum of activity against both Gram-positive and Gram-negative bacteria, inhibiting key enzymes responsible for antibiotic resistance.* -
- Ceftobiprole medocaril converts easily to its more effective form and has better water solubility than its parent compound, ceftobiprole, allowing for greater clinical application.*
$100 - $150
Hourly Rate
Ceftobiprole - a case study.
London, UK
2 hours ago
1 Received
- Ceftobiprole medocaril is a new cephalosporin antibiotic being tested for treating serious skin infections and hospital-acquired pneumonia, especially those caused by drug-resistant bacteria like MRSA.
- It effectively targets penicillin-resistant bacteria and has shown strong antibacterial activity in laboratory studies against a range of harmful Gram-positive and Gram-negative pathogens.
- Currently, it is undergoing Phase III clinical trials, with early results indicating a high cure rate and good tolerance among patients dealing with complicated skin infections and other related conditions.
$100 - $150
Hourly Rate
Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model.
London, UK
2 hours ago
1 Received
- Ceftobiprole, a new broad-spectrum antibiotic, shows effective in vivo action against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis, including difficult-to-treat strains.
- In a mouse study, ceftobiprole demonstrated a lower dose needed for protection compared to ampicillin, particularly against a beta-lactamase-producing E. faecalis strain, which ampicillin struggled to combat.
- The findings suggest that ceftobiprole could be a promising treatment option for human infections caused by E. faecalis, warranting further research.
$100 - $150
Hourly Rate
Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.
London, UK
2 hours ago
1 Received
- Ceftobiprole is a new cephalosporin antibiotic being tested against MRSA and was compared to vancomycin in a clinical trial for complicated skin infections.
- The trial involved 784 patients, showing similar cure rates for both drugs (93.3% for ceftobiprole vs 93.5% for vancomycin) with effective results for MRSA cases specifically.
- Adverse events were reported by around 52% of patients on ceftobiprole and 51% on vancomycin, with nausea and taste disturbance being the most common, but overall, ceftobiprole was deemed effective and well-tolerated.
$100 - $150
Hourly Rate
A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.
London, UK
2 hours ago
1 Received
- A randomized, double-blind trial compared the effectiveness of ceftobiprole monotherapy to a combination of vancomycin and ceftazidime in patients with complicated skin infections caused by gram-positive or gram-negative bacteria.
- Results showed similar clinical cure rates for both treatment groups, with ceftobiprole achieving a 90.5% cure rate compared to 90.2% for the combination therapy in the clinically evaluable population.
- The study concluded that ceftobiprole monotherapy is as effective as the combination therapy, with comparable rates of adverse events.
$100 - $150
Hourly Rate
Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity.
London, UK
2 hours ago
1 Received
- Ceftobiprole is a newly developed broad-spectrum cephalosporin antibiotic effective against MRSA and other Gram-positive and Gram-negative bacteria.
- It is administered as a prodrug, ceftobiprole medocaril, which is quickly converted to the active drug in the body and is mostly eliminated unchanged through the kidneys.
- The drug shows low binding to plasma proteins, minimal metabolism in the liver, and achieves steady-state concentrations in the body within the first day of dosing, with some slight differences in exposure levels between genders.
$100 - $150
Hourly Rate
New and emerging treatment of Staphylococcus aureus infections in the hospital setting.
London, UK
2 hours ago
1 Received
- MRSA (Methicillin-resistant Staphylococcus aureus) is a serious pathogen causing an increasing number of infections, posing high risks for complications and death in both hospitals and communities.
- Traditional treatment with vancomycin is becoming less effective due to emerging resistant strains, highlighting the urgent need for new antibiotics.
- Ceftobiprole, a new investigational cephalosporin, shows promise by targeting the resistant mechanisms of MRSA and has demonstrated similar effectiveness to vancomycin in clinical trials for treating serious skin infections.
$100 - $150
Hourly Rate
Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus.
London, UK
2 hours ago
1 Received
- The study evaluated how the antibiotic ceftobiprole is absorbed and distributed in bone tissue after being given to uninfected New Zealand White rabbits via subcutaneous injection.
- Higher doses of ceftobiprole (80 mg/kg) showed proportional increases in serum exposure and effective distribution in bone compared to lower doses (20 mg/kg), without drug accumulation over time.
- In a separate experiment on a rabbit model of osteomyelitis, ceftobiprole effectively reduced bacterial levels in infected bones more than other antibiotics tested, demonstrating its potential as a treatment option for resistant infections.
$100 - $150
Hourly Rate
Gateways to clinical trials.
London, UK
2 hours ago
1 Received
- The text lists various pharmaceutical compounds and drugs, including their generic names and some specific formulations.
- It highlights a wide range of treatments, focusing on diverse therapeutic areas like immunology, oncology, and infectious diseases.
- The mention of both established and experimental medications reflects ongoing research and development in the field of medicine.
$100 - $150
Hourly Rate
Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.
London, UK
2 hours ago
1 Received
- Ceftobiprole medocaril is an advanced cephalosporin antibiotic effective against several drug-resistant bacteria, including MRSA and certain resistant strains of pneumonia, but not effective against all types like ESBL-producing Enterobacteriaceae.
- * It is recommended to be administered in specific dosages for different types of infections, with clinical trials showing its effectiveness comparable to traditional antibiotics like vancomycin.
- * Though the overall side effects are similar to those of the comparison drugs, ceftobiprole may cause higher rates of nausea, vomiting, and an altered taste in some patients.
$100 - $150
Hourly Rate
Comparative study of the susceptibilities of major epidemic clones of methicillin-resistant Staphylococcus aureus to oxacillin and to the new broad-spectrum cephalosporin ceftobiprole.
London, UK
2 hours ago
1 Received
- * Ceftobiprole (BPR) is a new cephalosporin antibiotic that has shown strong effectiveness against various bacterial pathogens, including resistant forms of MRSA.
- * Research indicated that BPR is effective against MRSA strains with reduced susceptibility to other antibiotics, attributed to its high affinity for a key protein linked to antibiotic resistance.
$100 - $150
Hourly Rate
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
London, UK
2 hours ago
1 Received
- The study examined how well the new cephalosporin drug, ceftobiprole medocaril, mixed with 70 other medications during Y-site injection.
- Ceftobiprole was tested in three different solutions (5% dextrose, 0.9% sodium chloride, and lactated Ringer's) and was found to be compatible with 31 drugs while being incompatible with 32, with 7 showing variable compatibility based on the solution used.
- It was concluded that ceftobiprole should not be given at the same time as incompatible drugs to avoid potential issues like visible particles and turbidity in the mixture.
$100 - $150
Hourly Rate
In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.
London, UK
2 hours ago
1 Received
- Ceftobiprole medocaril is a new prodrug that effectively fights against MRSA and penicillin-resistant Streptococcus pneumoniae, showing strong bactericidal properties in lab settings.
- The study utilized mouse models to analyze the drug's pharmacokinetics and pharmacodynamics, measuring how it behaves in the body and its effect on bacterial infection.
- Findings indicated that the drug requires longer duration above the minimum inhibitory concentration (T > MIC) to be effective, with neutrophil presence boosting its activity against S. pneumoniae but having a minimal effect on MRSA.
$100 - $150
Hourly Rate
Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
London, UK
2 hours ago
1 Received
- Ceftobiprole is an investigational antibiotic in phase III trials, effective against various tough bacteria like MRSA and penicillin-resistant strains, but has limited activity against anaerobes.
- It has a low tendency to develop bacterial resistance and is quickly converted into its active form in the body, peaking shortly after infusion.
- Ceftobiprole requires dosage adjustments for patients with kidney issues due to its renal excretion and has a modest post-antibiotic effect against certain bacteria.
$100 - $150
Hourly Rate
Ceftobiprole medocaril: a new generation beta-lactam.
London, UK
2 hours ago
1 Received
- - Ceftobiprole is a new injectable cephalosporin antibiotic effective against methicillin-resistant staphylococci and other tough bacteria due to its strong binding to penicillin-binding proteins.
- - It is administered as a prodrug (ceftobiprole medocaril) due to low water solubility and is generally well tolerated, though it may cause a caramel-like taste disturbance.
- - Clinical trials show potential for using ceftobiprole as a standalone treatment for complicated skin infections, particularly those caused by MRSA, reducing the need for combination therapy.
$100 - $150
Hourly Rate
Gateways to clinical trials. December 2008.
London, UK
2 hours ago
1 Received
- "Gateways to Clinical Trials" is a comprehensive guide summarizing recent clinical trials from the latest literature and conferences.
- It compiles data from the Clinical Trials Knowledge Area of Prous Science Integrity, a drug discovery portal.
- The focus of this issue is on a diverse range of drugs, including AAV1/SERCA2a, Abatacept, and Adalimumab, among many others.
$100 - $150
Hourly Rate